

**Section 12 Notice                      Additional Information Required to Fulfill the Terms and Conditions for Conditional Registration**

***Product Name:***                      **WOCOSEN 100SL**  
***Registration Number:***        **24514**  
***Application Number:***        **2006-7612**  
***PMRA #:***                              **1437591**

During the conditional registration period which has been granted to *December 31, 2009*, the following information is to be generated and must be provided to the Pest Management Regulatory Agency by *December 31, 2008* and should indicate the reference numbers specified. A partial response to the outlined Terms and Conditions will not be accepted.

**PART 4                                      TOXICOLOGY**

---

**DACO:**                                      **4.5.12**  
**Title:**                                        **Acute Neurotoxicity Study (rat)**

**Required DATA:**        **The acute neurotoxicity study requested by the US EPA should also be submitted to the PMRA.**

**PART 5                                      EXPOSURE (OCCUPATIONAL AND/OR BYSTANDER)**

---

**DACO:**                                      **5.4 and 5.6**  
**Title:**                                        **Mixer/Loader/Applicator, Post-Application - Passive Dosimetry**

**Required DATA:**        Exposure estimates for spray and coat treatment operators (chemical operators), cleanup crew and maintenance/repair workers (millwrights) must be refined. The PMRA recommends the registrant generate product-specific and site-specific (i.e. joinery facilities) passive dosimetry data for these workers.

Refer to the *OECD Guidance Document for the Conduct of Studies of Occupational Exposure to Agricultural Pesticides* or the *EPA's OPPTS Test Guideline Series 875 - Occupational and Residential Exposure Test Guidelines: Group A - Applicator Exposure Monitoring Test Guidelines* (formerly Subdivision U) for details on conducting these types of studies. Prior to study generation, the applicant must submit protocols to the PMRA for comment.

**DACO:** 5.8  
**Title:** Dermal Absorption

**Required DATA:** If available, Janssen should submit the following dermal absorption studies:

**Hassler, S. 2000. The in vitro percutaneous absorption of [Phenyl-U-14] CGA 64250 formulated as TILT 250 EC (A-6097 K) through rat and human epidermis. Novartis Crop Protection AG, Basel, Switzerland. Study Report No. 044AM02, 04.01.2000 GLP, not published. Novartis File N\* CGA64250/4276.**

**Hassler, S. 2000. Dermal absorption of [Phenyl-U-14C] CGA 64250 formulated as Tilt 250 EC (A-6097 K) in the rat. Novartis Crop Protection AG, Basel, Switzerland. Study Report No. 044AM01, 09.02.2000 GLP, not published. Novartis File N\* CGA64250/4292.**